Patent application number | Description | Published |
20120142685 | ORGANIC COMPOUNDS - The present invention provides a compound formula I: (formula I) said compound is inhibitor of selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. Finally, the present invention also provides a pharmaceutical composition. | 06-07-2012 |
20120277215 | Organic Compounds - The present invention provides a compound of formula I: | 11-01-2012 |
20120295888 | USE OF AN ADRENAL HORMONE-MODIFYING AGENT - The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): | 11-22-2012 |
20130184253 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS - The present invention provides a compound of formula I: | 07-18-2013 |
20130197016 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE - The use of vascular endothelial growth factor receptor 2 inhibitors or a pharmaceutically acceptable salt thereof for the treatment of ocular vascular disease is provided. Dosing regimes, including once weekly administration, of certain VEGF-R2 inhibitors are provided which deliver therapeutically effective concentrations of the VEGF-R2 compounds in ocular tissues for at least one week for the treatment of ocular vascular disease. | 08-01-2013 |
20130287789 | Organic Compounds - The present invention provides a compound of formula I: | 10-31-2013 |
20140171392 | Use of an Adrenal Hormone-Modifying Agent - The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): | 06-19-2014 |
20140349995 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS - The present invention provides a compound of formula I: | 11-27-2014 |
20140357621 | Organic Compounds - The present invention provides a compound of formula I: | 12-04-2014 |